From: Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
Characteristics | n = 63 |
---|---|
Patient age, median (range), y | 42 (16–65) |
Diagnosis at transplant, no. (%) | |
Malignant diseases | |
Acute myeloid leukemia | 23 (36.5%) |
Chronic myeloid leukemia | 9 (14.3%) |
Acute lymphoblastic leukemia | 9 (14.3%) |
Chronic lymphocytic leukemia | 4 (6.3%) |
Multiple myeloma | 2 (3.2%) |
Non-Hodgkin lymphoma | 3 (4.8%) |
Hodgkin lymphoma | 2 (3.2%) |
Myelodysplastic syndrome | 4 (6.3%) |
Non-malignant diseases | |
Severe aplastic anemia | 4 (6.3%) |
Paroxysmal nocturnal hemoglobinuria | 3 (4.8%) |
Donor age, median (range), y | 39 (6–65) |
Patient gender (donor/recipient), n. (%) | |
Male/male | 23 (36.5%) |
Male/female | 10 (15.9%) |
Female/male | 13 (20.6%) |
Female/female | 17 (27%) |
Donor type, no. (%) | |
HLA-identical related | 61 (96.8%) |
HLA-matched unrelated | 2 (3.2%) |
Conditioning regimen, no. (%) | |
High dose | 46 (73%) |
Low dose | 17 (27%) |
Source of stem cells, no. (%) | |
Bone marrow | 23 (36.5%) |
Mobilized blood | 40 (63.5%) |
GVHD prophylaxis, no. (%) | |
Cyclosporine plus methotrexate | 49 (77.7%) |
Cyclosporine plus mycophenolate mofetil | 14 (22.3%) |
Acute GVHD, no. (%) | 17 (27%) |
Grade 0-I | 46 (73%) |
Grade II-IV | 17 (27%) |
Donor/recipient CMV serologic status, n° (%) | |
IgG +/IgG+ | 55 (87.2%) |
IgG +/IgG - | 3 (4.8%) |
IgG -/IgG - | 2 (3.2%) |
IgG-/igG+ | 2 (3.2%) |
Not determined | 1 (1.6%) |